Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$8.41 USD
+0.22 (2.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $8.40 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Earnings News For SAGE
-
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
-
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
-
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
-
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
-
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report?
-
Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates
-
Will Sage Therapeutics, Inc. (SAGE) Report Negative Earnings Next Week? What You Should Know
-
Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?
-
Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%
-
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Misses Revenue Estimates
-
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for
-
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
-
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
-
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for
-
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates
-
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
-
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
-
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Lags Revenue Estimates
-
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Misses Revenue Estimates
-
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Lags Revenue Estimates
-
Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: Should You Buy?